IRLAB is a world-leading brand in the field of neuropharmacology, with a special focus on understanding Parkinson's disease. Rooted in Nobel Prize-winning research, IRLAB has gained recognition and respect for its expertise in complex CNS disorders. With a strategic R&D pipeline, IRLAB is dedicated to developing powerful new treatments for Parkinson's disease at every stage of the patient's journey.

Parkinson's is a prevalent neurodegenerative disease, and the number of affected individuals is projected to double by 2040. To address this challenge, IRLAB has developed a disruptive technology platform called ISP, which accelerates the discovery of new CNS drug candidates. Utilizing advanced machine learning techniques, ISP informs the design of potential drug candidates with the desired therapeutic effects.

This platform has already led to the discovery of three clinical candidates and two pending Phase I candidates. IRLAB's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb trials and aim to treat challenging symptoms of Parkinson's disease, such as dyskinesias, psychosis, cognitive decline, impaired balance, and falls. Additionally, IRLAB is developing two preclinical candidates targeting cognitive impairment and apathy.

IRL1117, an oral treatment, aims to address the hallmark symptoms of Parkinson's without inducing complications. With the growing elderly population and the increasing need for effective treatments, IRLAB is poised to make a significant impact in the pharmaceutical industry. Their shares are traded on Nasdaq Stockholm Main Market Mid Cap, and the company is headquartered in Gothenburg, Sweden